Journal Article FZJ-2021-00351

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid

 ;  ;  ;  ;  ;  ;  ;  ;

2021
Elsevier New York, NY [u.a.]

European journal of pharmaceutical sciences 156, 105581 - () [10.1016/j.ejps.2020.105581]

This record in other databases:      

Please use a persistent id in citations:   doi:

Abstract: Amyloid-β (Aβ) plays a central role in the development and progression of Alzheimer's disease (AD) with Aβ oligomers representing the most toxic species. The all-d-enantiomeric peptide RD2, which recently successfully completed clinical phase I, specifically eliminates Aβ oligomers in vitro as well as in vivo and improves cognitive deficits in various transgenic AD mouse models even after oral administration. To further enhance the oral absorption of RD2, folic acid has been conjugated to the d-peptide promoting an endocytosis-mediated uptake via a folate receptor located in the intestine. Two different conjugation strategies were selected to obtain prodrugs with folic acid being cleaved after intestinal absorption releasing unmodified RD2 in order to enable RD2's unaltered systemic efficacy. Both conjugates remained stable in simulated gastrointestinal fluids. But only one of them was suitable as prodrug as it was cleaved to RD2 in vitro in human blood plasma and liver microsomes and in vivo in mice after intravenous injection leading to a systemic release of RD2. Furthermore, the conjugate's permeability in vitro and after oral administration in mice was strongly enhanced compared to unconjugated RD2 demonstrating the prodrug's functionality. However, the conjugate seemed to have impaired the mice's wellbeing shortly after oral administration possibly resulting from strain-specific hypersensitivity to folic acid. Nevertheless, we assume that the prodrug is actually non-toxic, especially in lower concentrations as verified by a cell viability test. Furthermore, lower dosages can be applied with unaltered efficacy due to its enhanced oral absorption.

Classification:

Contributing Institute(s):
  1. Strukturbiochemie (IBI-7)
  2. Analytik (ZEA-3)
Research Program(s):
  1. 5244 - Information Processing in Neuronal Networks (POF4-524) (POF4-524)

Appears in the scientific report 2021
Database coverage:
Medline ; Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 ; Embargoed OpenAccess ; BIOSIS Previews ; Biological Abstracts ; Chemical Reactions ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; Index Chemicus ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Dokumenttypen > Aufsätze > Zeitschriftenaufsätze
Institutssammlungen > IBI > IBI-7
Institutssammlungen > ZEA > ZEA-3
Workflowsammlungen > Öffentliche Einträge
Publikationsdatenbank
Open Access

 Datensatz erzeugt am 2021-01-18, letzte Änderung am 2022-02-23


Published on 2020-10-06. Available in OpenAccess from 2021-10-06.:
Volltext herunterladen PDF
Externer link:
Volltext herunterladenFulltext by OpenAccess repository
Dieses Dokument bewerten:

Rate this document:
1
2
3
 
(Bisher nicht rezensiert)